[1]毕淑利 姚朱华.作用于环磷酸鸟苷的抗心力衰竭药物作用机制及研究进展[J].心血管病学进展,2022,(8):735-738.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.017]
　BI Shuli,YAO Zhuhua?/html>.Mechanisms and Research Progress of Anti-Heart Failure Drug?argeting Cyclic Guanosine Monophosphate[J].Advances in Cardiovascular Diseases,2022,(8):735-738.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.017]
点击复制

作用于环磷酸鸟苷的抗心力衰竭药物作用机制及研究进展(/HTML)
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年8期
页码:
735-738
栏目:
综述
出版日期:
2022-08-25

文章信息/Info

Title:
Mechanisms and Research Progress of Anti-Heart Failure Drug?argeting Cyclic Guanosine Monophosphate
作者:
毕淑利1 姚朱华2; 3
(1.南开大学医学院,天津 300071;2.天津市人民医院心内科,天津 300121;3.南开大学人民医院转化医学研究院,天津 300121)
Author(s):
BI Shuli1;  YAO Zhuhua2; 3?/html>
(1.School of MedicineNankai UniversityTianJin 300071 China2.Department of Cardiology,Tianjin Union Medical CenterTianJin 300121 China3.The Institute of Translational Medicine,Tianjin Union Medical Center of Nankai UniversitTianJin 300121 China)
关键词:
环磷酸鸟苷; 鸟苷酸环化酶; 心力衰竭; 药物治疗
Keywords:
Cyclic guanosine monophosphate; Guanylate cyclase; Heart failure; Drug therapy
DOI:
10.16806/j.cnki.issn.1004-3934.2022.08.017
摘要:
随着对心力衰竭相关机制的深入研究，心力衰竭治疗理念已从早期的“强心、利尿、扩血管”时代发展至目前的神经内分泌调控时代。其中作为细胞内信号转导的第二信使环磷酸鸟苷（cGMP）越来越受到重视，其激活下游cGMP依赖的蛋白激酶G等分子产生重要的生物学效应，是心力衰竭治疗的潜在靶点。部分作用于一氧化氮-可溶性鸟苷酸环化酶-cGMP信号通路或利钠肽-颗粒型鸟苷酸环化酶-cGMP信号通路增加cGMP浓度的药物已在临床得到广泛应用。现对基于该途径研发的直接或间接通过cGMP发挥药理学作用的抗心力衰竭药物做简要综述。
Abstract:
With further research about mechanisms associated with heart failure,whose treatment has been from“inotropic,diuretic and vasodilators” in earlier times to neurohormonal regulation in the modern era. Particularly,cyclic guanosine monophosphate (cGMP),as a second messenger in intracellular signal transduction,is becoming more and more attractive. It activates cGMP-dependent protein kinases G and other molecules ,which in turn generate important biological effects,servering as potential therapeutic target of anti-heart failure. Part drugs acting on nitric oxide-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate signaling pathways and natriuretic peptide- particulate guanylate cyclase(pGC)-cGMP signaling pathways have been widely used in the clinic,which increase cGMP concentration. This paper reviews the developing of anti-heart failure drugs,based on these two pathways,which induce pharmacologocal response directly and indirectly targeting cGMP.

参考文献/References:

[1] 国家卫生计生委合理用药专家委员会,中国药师协会. 心力衰竭合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版),2019,11(7):1-78.

[2] Mamas MA,Sperrin M,Watson MC,et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland[J]. Eur J Heart Fail,2017,19(9):1095-1104.?/span>
[3] Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors[J]. Physiol Rev,2016,96(2):751-804.?/span>
[4] Volpe M,Carnovali M,Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure:from molecular basis to treatment[J]. Clin Sci (Lond),2016,130(2):57-77.?/span>
[5] Stasch JP,Pacher P,Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease[J]. Circulation,2011,123(20):2263-2273.?/span>
[6] Münzel T,Steven S,Daiber A. Organic nitrates:update on mechanisms underlying vasodilation,tolerance and endothelial dysfunction[J]. Vascul Pharmacol,2014,63(3):105-113.?/span>
[7] Münzel T,Daiber A,Mülsch A. Explaining the phenomenon of nitrate tolerance[J]. Circ Res,2005,97(7):618-628.?/span>
[8] den Uil CA,Brugts JJ. Impact of intravenous nitroglycerin in the management of acute decompensated heart failure[J]. Curr Heart Fail Rep,2015,12(1):87-93.?/span>
[9] Bice JS,Keim Y,Stasch JP,et al. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size[J]. Cardiovasc Res,2014,101(2):220-228.?/span>
[10] Gheorghiade M,Greene SJ,Filippatos G,et al. Cinaciguat,a soluble guanylate cyclase activator:results from the randomized,controlled,phase Ⅱb COMPOSE programme in acute heart failure syndromes[J]. Eur J Heart Fail,2012,14(9):1056-1066.?/span>
[11] Bonderman D,Ghio S,Felix SB,et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction:a phase Ⅱb double-blind,randomized,placebo-controlled,dose-ranging hemodynamic study[J]. Circulation,2013,128(5):502-511.?/span>
[12] Bonderman D,Pretsch I,Steringer-Mascherbauer R,et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1):a randomized,double-blind,placebo-controlled,single-dose study[J]. Chest,2014,146(5):1274-1285.?/span>
[13] Boettcher M,Thomas D,Mueck W,et al. Safety,pharmacodynamic,and pharmacokinetic characterization of vericiguat:results from six phase Ⅰ studies in healthy subjects[J]. Eur J Clin Pharmaco,2021,77(4):527-537.?/span>
[14] Gheorghiade M,Greene SJ,Butler J,et al. Effect of vericiguat,a soluble guanylate cyclase stimulator,on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction:the SOCRATES-REDUCED randomized trial[J]. JAMA,2015,314(21):2251-2262.?/span>
[15] Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2020,382(20):1883-1893.?/span>
[16] Pieske B,Maggioni AP,Lam CSP,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study[J]. Eur Heart J,2017,38(15):1119-1127.?/span>
[17] Armstrong PW,Lam CSP,Anstrom KJ,et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction:the VITALITY-HFpEF randomized clinical trial[J]. JAMA,2020,324(15):1512-1521.?/span>
[18] O’Connor CM,Starling RC,Hernandez AF,et al. Effect of nesiritide in patients with acute decompensated heart failure[J]. N Engl J Med,2011,365(1):32-43.?/span>
[19] Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial[J]. JAMA,2002,287(12):1531-1540.?/span>
[20] McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.?/span>
[21] Velazquez EJ,Morrow DA,de Vore AD,et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med,2019,380(6):539-548.?/span>
[22] Solomon SD,McMurray JJV,Anand IS,et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med,2019,381(17):1609-1620.?/span>
[23] Maddox TM,Januzzi JL Jr,Allen LA,et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment:answers to 10 pivotal issues about heart failure with reduced ejection fraction:a report of the American College of Cardiology solution set oversight committee[J]. J Am Coll Cardiol,2021,77(6):772-810.?/span>
[24] 孙宁玲,王鸿懿,喜杨. 沙库巴曲缬沙坦对比血管紧张素受体阻滞药治疗原发性高血压的疗效:网状荟萃分析[J]. 中华高血压杂志,2021,29(8):748-756.?/span>
[25] Kang H,Zhang J,Zhang X,et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease:a meta-analysis[J]. Eur J Pharmacol,2020,884:173444.?/span>
[26] Redfield MM,Chen HH,Borlaug BA,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial[J]. JAMA,2013,309(12):1268-1277.?/span>
[27] Shah SJ,Kitzman DW,Borlaug BA,et al. Phenotype-specific treatment of heart failure with preserved ejection fraction:a multiorgan roadmap[J]. Circulation,2016,134(1):73-90.?/span>
[28] Rainer PP,Kass DA. Old dog,new tricks:novel cardiac targets and stress regulation by protein kinase G[J]. Cardiovasc Res,2016,111(2):154-162.?/span>
[29] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.

相似文献/References:

[1]高源 郑刚 李嫣红 张鼎.维利西呱治疗心力衰竭新进展[J].心血管病学进展,2021,(8):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]
　Gao Yuan Zheng Gang Li Yan Hong Zhang Ding.Treatment of Heart Failure with Vericiguat[J].Advances in Cardiovascular Diseases,2021,(8):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]

备注/Memo

备注/Memo:
基金项目：天津市卫生健康科技项目（ZC20080）
通信作者：姚朱华，E-mail: tjyzhpci@163.com?#160
更新日期/Last Update: 2022-10-08